A–D, FGFR3 gatekeeper mutations detected in 4 patients.

Slides:

Advertisements

Similar presentations

© Copyright 2009 by the American Association for Clinical Chemistry Enrichment and Detection of Rare Alleles by Means of Snapback Primers and Rapid-Cycle.

Advertisements

Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:

The expression and signaling of FGFR3 in WM cells.

S4 Fig. REMARK diagram of course selection for analysis of ctDNA pre-treatment and for ctDNA change after the first and second cycle of chemotherapy. Courses.

A, baseline and 4-week PET scan from patient 2 (MET c

Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.

Diagnostic approaches to measure the impact of cancer therapies on clonal evolution. Diagnostic approaches to measure the impact of cancer therapies on.

Copy-number alterations in an archival breast cancer sample.

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

FGFR and PRKA gene rearrangements in CCAs

Figure 1. Plasma next-generation sequencing (NGS) assay workflow, comparison of variant allelic fraction with ... Figure 1. Plasma next-generation sequencing.

Concentrations of abemaciclib in plasma and cerebrospinal fluid (CSF).

Scatterplot showing the association between baseline weight and weight change at 1 year, relative to baseline for each treatment group. Scatterplot showing.

Quantification of MHC-I, β2m, and T-cell subsets.

Presentation and progression of glioblastoma with PNET features in an adult patient. Presentation and progression of glioblastoma with PNET features in.

High-level clonal amplification of FGFR2 predicts for sensitivity to FGFR inhibitor. High-level clonal amplification of FGFR2 predicts for sensitivity.

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

Changes in the ratio of (EPA+DHA):AA in the breast triacylglyceride compartment. Changes in the ratio of (EPA+DHA):AA in the breast triacylglyceride compartment.

Partial pedigrees for novel INS mutations identified in probands with MODY and young type 2 diabetes. Partial pedigrees for novel INS mutations identified.

Changes in tumor sizes, CA-125, serum ceruloplasmin, and copper levels in 5 patients with platinum-resistant high-grade epithelial ovarian cancer who received.

Colony-forming capacity of CD34+ cells with and without CLL-1 expression. Colony-forming capacity of CD34+ cells with and without CLL-1 expression. CD34+

JAK2V617F leads to increased 5-hmC and genome-wide loss of cytosine methylation in primary patient samples. JAK2V617F leads to increased 5-hmC and genome-wide.

Predictive value of the FGFR3 mutation assay increases with multiple consecutive FGFR3-positive urine samples. Predictive value of the FGFR3 mutation assay.

FGFR3 mutation analysis of a selection of urine samples from patients included with an FGFR3-mutant (MT) tumor. FGFR3 mutation analysis of a selection.

Positive correlations between disease course and treatment-induced immune responses. Positive correlations between disease course and treatment-induced.

The I1307K APC gene variant was identified using primers designed to detect the I1307K. The I1307K APC gene variant was identified using primers designed.

Personalized, 16-plex assays accurately detect ctDNA ahead of clinical relapse. Personalized, 16-plex assays accurately detect ctDNA ahead of clinical.

A, Proportion of variants detected in the MMR genes.

Biological effects of BRAF silencing: growth curves of A375 (A) and ARO (B) cell lines in the absence or presence of doxycycline. Biological effects of.

Plasma and tissue EGFR allele analyses.

Positions of the EGFR exon 20 insertions identified over a 3-year period and comparison with the spectrum of EGFR exon 19 and HER2 insertion mutations.

Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.

A, change in Ki-67 expression (percent of cells staining positive) over the course of the intervention. A, change in Ki-67 expression (percent of cells.

Time course of a G2-M arrest in response to 6-TG compared with IR and VP-16, showing that 6-TG induced a delayed G2-M arrest in MMR+ cells. Time course.

Tumor and serum levels of murine IL-12.

Immunologic and pharmacokinetic studies.

Duration of treatment and intervals of radiographic and ctDNA response

WP1066 inhibits the progression of OCIM2 cells through the cell cycle.

Distribution of FGFR aberrancies in urothelial cancers.

Intratumoral changes in critical lymphocyte populations and numbers after NKTR-214 treatment. Intratumoral changes in critical lymphocyte populations and.

Location of the ER mutations and frequencies per cohort.

Selected overview of clinical trials evaluating FGFR signaling–targeted therapies currently under development (monotherapy). Selected overview of clinical.

Correlation of PTEN loss in melanoma cells with an immune resistance phenotype. Correlation of PTEN loss in melanoma cells with an immune resistance phenotype.

Efficacy summary for patients with gastric/GEJ adenocarcinoma (part B)

Increased frequency and number of KLL-specific clonotypes in tumors is associated with improved MCC-specific survival. Increased frequency and number of.

Representative patient responses to ulixertinib.

Mean percentage change from baseline in total IGF-I and the R1507 serum concentration values following a single i.v. administration of R mg/kg (n.

The best response for target lesions per patient for patients with target lesions assessed at baseline and at least 1 follow-up. The best response for.

Rapid autopsy reveals interlesional and intralesional heterogeneity of resistance. Rapid autopsy reveals interlesional and intralesional heterogeneity.

Concordance between the genomic landscape identified by whole-exome sequencing of plasma cfDNA and tumor; DNA and recurrence of KDR/VEGFR2 oncogenic mutations.

Inhibition of CD20 mRNA expression by ibrutinib correlates with reduced NF-κB activity. Inhibition of CD20 mRNA expression by ibrutinib correlates with.

Ibrutinib decreases ofatumumab-mediated complement-dependent cytotoxicity. Ibrutinib decreases ofatumumab-mediated complement-dependent cytotoxicity. A,

Tracking resistance to TRKA inhibition in ctDNA of a patient with colorectal cancer. Tracking resistance to TRKA inhibition in ctDNA of a patient with.

BRAF in-frame deletion confers response to MAPK inhibition.

Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. A,

Blockade of cell cycle at G2-M phase in Bel-7402 cells treated with IG-105. Blockade of cell cycle at G2-M phase in Bel-7402 cells treated with IG-105.

Renal hemodynamics. Renal hemodynamics. GFR (A), effective renal plasma flow (ERPF; B), and filtration fraction (FF; C) in patients with diabetes and with.

A, Changes in BRAFV600E cfDNA allele fraction from baseline after one dose of treatment for 12 patients with serial samples available, classified according.

Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.

THZ1 in combination with targeted therapy enhances cell death and hinders the establishment of drug-resistant colonies in diverse oncogene-addicted cellular.

In vivo efficacy of JAK inhibition in transformed Pax5+/− pro-B cells harboring Jak3V670A. In vivo efficacy of JAK inhibition in transformed Pax5+/− pro-B.

FGFR2 amplification in primary human gastric tumors predicts for response to NVP-BGJ398. FGFR2 amplification in primary human gastric tumors predicts for.

FGF19 amplification in liver cancer cell lines is associated with response to NVP-BGJ398. FGF19 amplification in liver cancer cell lines is associated.

Curcumin decreases viability and proliferation of Bcr-Abl-expressing cells. Curcumin decreases viability and proliferation of Bcr-Abl-expressing cells.

NVP-BGJ398 inhibits proliferation of a subset of cancer cell lines.

High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies. High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies.

A, study design for measuring the feasibility, concordance, and accuracy of a plasma-based cfDNA sequencing test compared with biopsy-based sequencing.

Treatment-induced immune cell changes.

BIM expression predicts the response of patients with EGFR-mutant lung cancers. BIM expression predicts the response of patients with EGFR-mutant lung.

Low initial levels of CD4+ Tregs, proliferating CD8+, and Granzyme B+ CD8+ T cells and high posttreatment tumor MHC class II expression predict better.

Presentation transcript:

A–D, FGFR3 gatekeeper mutations detected in 4 patients. A–D,FGFR3 gatekeeper mutations detected in 4 patients. A,C2D1; B,C2D1, C6D28, C8D28; C,C2D1; D,C9. E,FGFR3 mutations in the cfDNA of 1 patient during the course of treatment with BGJ398. F and G, Change in allele fraction of FGFR3 after the first cycle of treatment and correlation with (F) time on study and (G) best percentage change from baseline. P values were calculated using a two-sided t test. Increase is defined as Cycle 2 FGFR3 allele fraction higher than the baseline value, whereas decrease is defined as Cycle 2 FGFR3 allele fraction lower than the baseline value. aTime point with ctDNA level below the assay limit of detection (power < 0.8). Sumanta K. Pal et al. Cancer Discov 2018;8:812-821 ©2018 by American Association for Cancer Research